Rifapentine
Priftin (rifapentine) is a small molecule pharmaceutical. Rifapentine was first approved as Priftin on 1998-06-22. It is used to treat latent tuberculosis, mycobacterium infections, and pulmonary tuberculosis in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| respiratory tract diseases | D012140 |
Trade Name
FDA
EMA
Priftin
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| priftin | New Drug Application | 2025-05-21 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| pulmonary tuberculosis | EFO_1000049 | D014397 | A15 |
| latent tuberculosis | — | D055985 | Z22.7 |
| mycobacterium infections | — | D009164 | A31.9 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
72 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 12 | 11 | 19 | 7 | 9 | 51 |
| Latent tuberculosis | D055985 | — | Z22.7 | 7 | 5 | 11 | 4 | 4 | 26 |
| Infections | D007239 | EFO_0000544 | — | 1 | 2 | 4 | 1 | — | 7 |
| Hiv | D006678 | — | O98.7 | 2 | 2 | 1 | 1 | 1 | 6 |
| Hiv seropositivity | D006679 | — | — | 1 | 1 | — | 1 | — | 2 |
| Patient compliance | D010349 | — | — | — | — | — | 1 | — | 1 |
| Renal insufficiency | D051437 | — | N19 | — | — | — | 1 | — | 1 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | 3 | 3 | — | 3 | 10 |
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | 1 | 3 | 6 | — | — | 8 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 2 | — | 1 | — | 1 | 4 |
| Communicable diseases | D003141 | — | — | 1 | 2 | 1 | — | — | 3 |
| Mycobacterium infections | D009164 | — | A31.9 | — | 1 | 1 | — | — | 2 |
| Respiratory tract infections | D012141 | — | J06.9 | 1 | 1 | 1 | — | — | 2 |
| Mycobacterium tuberculosis | D009169 | NCBITaxon_1773 | — | 1 | — | 1 | — | — | 2 |
| Silicosis | D012829 | EFO_0007485 | J62 | — | — | 1 | — | 1 | 2 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | 1 | — | — | 1 |
| Infertility | D007246 | EFO_0000545 | — | — | — | 1 | — | — | 1 |
Show 6 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mycobacterium avium-intracellulare infection | D015270 | EFO_0007386 | — | — | 1 | — | — | — | 1 |
| Bacteremia | D016470 | EFO_0003033 | R78.81 | — | 1 | — | — | — | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
| Drug interactions | D004347 | — | — | 1 | — | — | — | — | 1 |
| Breast feeding | D001942 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | — | — | — | 1 | 1 |
| Hepatitis | D006505 | — | K75.9 | — | — | — | — | 1 | 1 |
| Addictive behavior | D016739 | EFO_0004347 | — | — | — | — | — | 1 | 1 |
| Silicotuberculosis | D012830 | — | J65 | — | — | — | — | 1 | 1 |
| Only child | D009863 | — | — | — | — | — | — | 1 | 1 |
| Adolescent development | D041923 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Rifapentine |
| INN | rifapentine |
| Description | Rifapentine, sold under the brand name Priftin, is an antibiotic used in the treatment of tuberculosis. In active tuberculosis it is used together with other antituberculosis medications. In latent tuberculosis it is typically used with isoniazid. It is taken by mouth.
|
| Classification | Small molecule |
| Drug class | antibiotics (rifamycin derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C6CCCC6)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C |
Identifiers
| PDB | — |
| CAS-ID | 61379-65-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1660 |
| ChEBI ID | 45304 |
| PubChem CID | 6323497 |
| DrugBank | DB01201 |
| UNII ID | XJM390A33U (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,354 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
360 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use